GPT and nasopharyngitis: Nasopharyngitis and alanine aminotransferase increase were the most frequently reported AEs in the phase 3 eltrombopag study [10], with nasopharyngitis and headache being the most frequent AEs in a phase 3 open-label extension study of eltrombopag [11].